Analysts’ View: Timken (TKR), CDK Global (CDK), Quest Diagnostics (DGX)

Brokerage Firm Stifel upgraded The Timken Company (NYSE:TKR) shares from Hold to Buy rating while increasing their price target from $52 to $60.

The Timken Company engineers, manufactures, and markets bearings, transmissions, gearboxes, belts, chains, lubrication systems, couplings, industrial clutches and brakes, and related products worldwide.


Investment Analysts at Barrington Research upgraded CDK Global, Inc. (NASDAQ:CDK) shares from Market Perform to Outperform rating with a rice target of $80.

CDK Global, Inc. provides integrated information technology and digital marketing solutions to the automotive retail and other industries worldwide.


Quest Diagnostics Incorporated (NYSE:DGX) shares were upgraded by analysts at Morgan Stanley from Equal-Weight to Overweight rating.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally.


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE.Info is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at